functions in response to specific biological signals. Its core approach focuses on “disease-responsive” therapies, where engineered cells are designed to sense the surrounding cellular environment and adjust their activity accordingly. This enables therapies that can switch on or off, or modulate activity levels, depending on disease state or tissue context, rather than operating in a constant active mode. The company’s platform supports multiplex gene control, meaning multiple genes can be regulated simultaneously within engineered cells. This capability is applied to developing next-generation cell therapies such as CAR-T cells and macrophages for oncology, as well as exploratory programs in genetic, inflammatory, and metabolic diseases.